miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
Lisa Svartdal Normann,Mads Haugland Haugen,Miriam Ragle Aure,Vessela N Kristensen,Gunhild Mari Mælandsmo,Kristine Kleivi Sahlberg
DOI: https://doi.org/10.2147/BCTT.S338404
2022-03-01
Breast Cancer: Targets and Therapy
Abstract:Lisa Svartdal Normann, 1– 3 Mads Haugland Haugen, 2 Miriam Ragle Aure, 3 Vessela N Kristensen, 3 Gunhild Mari Mælandsmo, 2, 4 Kristine Kleivi Sahlberg 1, 2 1 Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway; 2 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; 3 Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 4 Institute for Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, Norway Correspondence: Kristine Kleivi Sahlberg, Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway, Tel +47 98641229, Email Purpose: Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer forms, and we assessed the effect and mechanism of action of this miRNA in HER2+ breast cancer. Methods: Expression levels of miR-101-5p in two clinical datasets, TCGA and METABRIC, were compared between tumor and normal adjacent samples, and across molecular subtypes and HER2 status. The ability of miR-101-5p to sensitize for treatment with lapatinib, tucatinib and trastuzumab was explored in HER2+ breast cancer cells responding poorly to such targeted drugs. Proliferation and apoptosis assays and downstream protein analysis were performed. Results: Expression levels of miR-101-5p were significantly lower in tumor compared to normal adjacent tissue (p < 0.001), and particularly low in HER2+ tumors, both the HER2-enriched subtype (p ≤ 0.037) and clinical HER2-status (p < 0.001). In a HER2+ cell line (KPL4) responding poorly to targeted drugs, miR-101-5p overexpression inhibited proliferation (p < 0.001), and combinatorial treatment with lapatinib and trastuzumab significantly further decreased this inhibition (p = 0.004). Proteomic data and in silico analyses revealed PI3K/Akt- and HER2-pathways among the predicted regulated pathways. miR-101-5p alone (p = 0.018) and in combination with lapatinib and trastuzumab (p < 0.001) induced apoptosis, while the targeted drugs alone did not exert any significant effect neither on proliferation nor apoptosis. Conclusion: miR-101-5p acts as a tumor suppressor by inducing apoptosis in HER2+ breast cancer and sensitizes cells with initially poor response to lapatinib and trastuzumab. Keywords: microRNA, targeted treatment, apoptosis, sensitize Human epidermal growth factor receptor 2 positive (HER2+) breast cancer is an aggressive disease that accounts for about 15% of all breast cancer cases. 1,2 HER2+ breast cancer cells have an overexpression of the tyrosine kinase HER2 on their surface, which initiates signaling pathways that regulate cellular growth, proliferation and survival. Based on a breast tumor's expression of hormone-receptors, HER2 and Ki-67 protein levels, they are categorized as either luminal A, luminal B, triple-negative or HER2-enriched. The latter shows the highest rate of local recurrence and distant metastasis, in addition to the lowest 10-year recurrence free survival. 3 There are multiple drugs that specifically target and inhibit HER2 in clinical use, including monoclonal antibodies (trastuzumab, pertuzumab, margetuximab), small molecular kinase inhibitors (lapatinib, neratinib, tucatinib) and monoclonal antibodies linked to chemotherapy (trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki). It is expected that current recurrence rates will decrease in follow-up studies where larger portions of the patients have received targeted therapy. 3 However, despite the available targeted therapies, some patients still experience disease progression upon primary or acquired resistance. The majority of patients with HER2+ metastatic breast cancer die from their disease, 4–6 and a continuous search for improved treatment options is needed. MicroRNAs (miRNAs) are short (18–24 nucleotides in length), single-stranded, non-coding, post-transcriptional regulators of cellular processes. 7 They are endogenously expressed in cells and regulate gene expression by binding to complementary messenger RNA (mRNA) strands. This binding leads to mRNA degradation or prevention of translation, and thus affects the proteome and is considered to participate in regulation of numerous biological processes in the cell. During the synthesis of miRNA, nucleotide duplexes with a 3'-end (−3p) and 5'-end (−5p) are cleaved into single strands. Historical -Abstract Truncated-